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Parenteral nutrition (PN) is a life-saving therapeutic approach that provides adequate nutrition to chil-dren and newborns with severe intestinal failure or 
who require an intestinal rest period due to necrotizing 
enterocolitis, intestinal atresia, pseudo-obstruction, or 
other motility disorders.1,2 PN is also used as nutrition sup-
port for preterm neonates.3 Unfortunately, in newborns, 
PN induces sometimes irreversible and even fatal liver 
injury.4 Many studies have reported an association between 
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liver dysfunction and PN, with an incidence ranging from 
15% to 85%. In pediatric aged patients, fibrosis, portal 
inflammation, cholestasis, proliferation of bile ducts, and 
hydropic degeneration are the main histological find-
ings.5-10 In preterm babies, canalicular cholestasis is the 
first histological sign of PN-induced hepatobiliary dysfunc-
tion and can be detected as early as 5 days after initiation 
of PN. After 2 weeks of PN, intracellular cholestasis is 
detected,9 and proliferation of bile ducts and fibrosis devel-
ops mainly after 8 weeks of PN, with incidences as high as 
100% after 28 weeks. The risk of developing liver complica-
tions is higher in underweight newborns treated with PN 
for more than 2 weeks as compared with normal-weight 
infants.10,11-13 However, despite numerous studies that have 
suggested several potential etiological factors, including 
infections, toxins, excess of sugars and calories, or bile acid 
(BA) toxicity, the pathogenesis of PN-induced liver compli-
cations has yet to be precisely defined.4 There is evidence 
that reduced enterohepatic circulation of BA and increased 
levels of phytosterols, which are highly concentrated in 
Background: Patients receiving parenteral nutrition (PN) fre-
quently exhibit liver dysfunction. The authors previously 
reported that plant sterols of lipid emulsions added to the nutri-
tional solution of newborns receiving PN accumulate in plasma 
and cell membranes and may contribute to the development of 
cholestasis. Conjugated bile acids (BA) have been shown to be 
useful markers of cholestasis. Plasma levels of several BA in 
newborns were quantified after administration of PN for less 
than 2 weeks. Methods: Plasma samples from 15 healthy control 
infants (CN), 22 patients who had received PN for 3–15 days 
(T1), and 9 patients scheduled to receive PN (T0) were ana-
lyzed. After a simple extraction procedure, plasma BA were 
analyzed by liquid chromatography–tandem mass spectrometry 
using a quantitative isotope dilution method. Results: The con-
centrations of BA did not differ significantly between controls 
and patients before PN (CN vs T0), with the exception of 
glycocholic acid (GCA; 2.30 ± 2.60 µM vs 7.29 ± 5.39 µM, 
respectively). There was a significant difference in several BA 
between controls and patients after PN (2.30 ± 2.60 µM vs 7.61 ± 
6.46 µM for GCA, respectively; 4.02 ± 3.49 µM vs 11.88 ± 11.05 
µM for taurocholic acid [TCA], respectively; and 4.81 ± 3.49 µM 
vs 13.58 ± 12.22 µM for taurochenodeoxycholic + taurodeoxy-
cholic + tauroursodeoxycholic acids [TCDCA+TDCA+TUDCA], 
respectively). Conclusions: In newborns receiving PN, a 
short period of PN is associated with an early increase of some 
conjugated BA. These results suggest that GCA, TCA, and 
TCDCA+TDCA+TUDCA levels could be used as early markers 
of PN-related cholestasis. (JPEN J Parenter Enteral Nutr. 
2010;34:538–541)
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many lipid emulsions used for PN, might increase the risk 
of cholestasis.14,15 However, PN-associated liver dysfunc-
tion due to lipids has been attributed mainly to impaired 
immune defenses and altered inflammatory responses.16 
Another possibility is that an immature hepatic secretory 
apparatus, particularly in premature newborns, predis-
poses the infant to cholestasis.17 Thus, insults such as PN 
might have a substantial impact on hepatic secretory func-
tion, resulting in conjugation but not excretion of BA into 
bile and subsequent increases in serum concentrations. 
Elevated concentrations of serum BA represent the earliest 
and most sensitive indicator of cholestasis, occurring 7–29 
days before cholestatic histological changes are seen.18
Here we quantified plasma tauro-conjugated and glyco-
conjugated BA in preterm and term newborns receiving PN 
for prematurity, respiratory diseases, or intolerance to enteral 
feeding. The aim of the study was to determine whether 
conjugated BA could be used early as sensitive markers of 
cholestasis and, therefore, potentially for monitoring the 
effects of therapy. Levels of BA in plasma were analyzed by 
liquid chromatography–tandem mass spectrometry (LC-ESI/
MS/MS) using the isotope dilution technique.
Experimental Procedure
Subjects
Study participants consisted of 22 term and preterm new-
borns who had received 3–15 days of PN (T1) and 15 
healthy newborns as a control (CN). Blood samples were 
also collected from patients requiring PN before the ini-
tiation of artificial nutrition (T0; n = 11). The patients of 
the T0 group were not randomized, and inclusion was 
based on the possibility, related to clinical condition of 
patient, of taking a blood sample before starting PN. 
Two infants in the T0 group were excluded because of 
insufficient plasma samples. Clinical characteristics and 
biochemical plasma markers of liver disease for each 
group are listed in Table 1. A full description of the 
patients and protocol has been published previously.19 
Informed written consent was obtained from the parents 
of enrolled newborns. The study protocol was approved 
by the ethics committee of Fatebenefratelli Hospital.
Analysis of Conjugated BA
Plasma levels of glycine- and taurine-conjugated BA were 
analyzed by LC-ESI/MS/MS using the isotope dilution 
technique. Samples from the T1 group were taken 12 
hours after the end of the last lipid infusion.
The procedure for extraction of BA from plasma was 
as follows. Sample (0.05 mL) was mixed with 0.1 mL of 
methanol containing fixed amounts of the following 4 
internal standards labeled with stable isotopes: trihydroxy-
lated taurocholic and glycocholic acids ([d-4]TCA, 5 µM 
and [d-4]GCA, 6 µM, respectively), and dihydroxylated 
taurochenodeoxycholic and glycochenodeoxycholic acids 
([d-4]TCDCA, 3 µM and [d-4]GCDCA, 5 µM, respec-
tively). Samples were vortexed and then sonicated for 10 
minutes, followed by the addition of 0.85 mL of pure 
methanol. Samples were sonicated again for 20 minutes 
and then subjected to centrifugation at 6,000 × g for 10 
minutes at 8°C. Supernatants were collected and dried at 
37°C under a gentle stream of nitrogen. The resultant 
residue was resuspended in 0.2 mL of mobile phase, and 
an aliquot (0.03 mL) was removed for analysis.
A high-performance liquid chromatography (HPLC) 
system with an autosampler (Alliance 2695; Waters, 
Milford, MA) was coupled with a triple quadrupole mass 
spectrometer equipped with an electrospray ion source 
operating in negative mode (Micromass Quattromicro; 
Waters). The mobile phase consisted of 2-propanol/water 
(60/40), and the flow rate was maintained at 0.07 mL/
min. Mass spectrometry was carried out as follows. 
Briefly, glycine- and taurine-conjugated di- and trihy-
droxylated BA and internal standards were individually 
dissolved in methanol at a final concentration of 1 mg/
mL. These standards were diluted to a concentration of 
50 µg/mL and used to determine the working conditions 
for HPLC and mass spectrometer for optimal resolution 
and abundance of ion signals. The conditions were as fol-
lows: capillary voltage, 3.20 kV; cone voltage, 30 V; source 
temperature, 120°C; desolvation temperature, 250°C; 
Table 1.  Clinical and Biochemical Characteristics in Healthy Control (CN) Infants 
and in Patients Before (T0) and After (T1) Parenteral Nutrition (PN) Reported as Mean (SD)
CN (n = 15) Before PN, T0 (n = 9)      After PN, T1 (n = 22)
Gestational age, wk 35 (4) 31 (5) 34 (4)
Birth weight, g 2531 (982) 1554 (586)a 2223 (965)
Total bilirubin, mg/dL 1.6 (0.7) 3.66 (1.99)a 3.73 (3.15)a
γ-glutamyltransferase, IU/L 72 (19) 155 (104) 122 (99)
Alanine transaminase, IU/L 10 (4) 16 (8) 21 (25)
aP < .05 vs CN (analysis of variance with Bonferroni correction).
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desolvation gas flow, 300 L/h; gas cell pirani, 0.0028 
mbar. Collision cell energy was 40 eV and 65 eV for gly-
cine- and taurine-conjugated BA, respectively. For quan-
titative analysis, precursor ions of the 74 m/z fragment for 
glycine conjugates and of the 80 m/z fragment for taurine 
conjugates were monitored using the specific scan mode 
(PI) of the MS/MS system. Acquisition mass ranges were 
from 420 to 500 and from 470 to 550 for glycine and 
taurine conjugates, respectively, and the run time was 3 
minutes. For each analyte, a calibration curve was used to 
calculate the concentration of BA in samples. Calibration 
points were obtained using a plasma pool enriched with 
the following standards: GCDCA (40 µM), GCA (50 
µM), TCDCA (12 µM), and TCA (30 µM). The enriched 
plasma was diluted (1:2 to 1:64) with unenriched plasma 
to obtain a range of concentrations. Correlation coeffi-
cients (r) of the calibration curves ranged from 0.998 to 
0.999. Method imprecision was calculated for 3 different 
concentrations of enriched plasma as follows: GCDCA, 
40 µM, 10 µM, and 0.625 µM; GCA, 50 µM, 12.5 µM, 
and 0.78 µM; TCDCA, 12 µM, 3 µM, and 0.016 µM; and 
TCA, 30 µM, 7.5 µM, and 0.47 µM. Values ranged 
4.8%–8.7% for GCDCA, 3.3%–12.6% for GCA, 6.3%–
17.5% for TCDCA, and 4.1%–14.5% for TCA.
Statistical Analysis
Differences in plasma levels of conjugated BA among 
CN, T0 (before PN), and T1 (after PN) infants were ana-
lyzed by analysis of variance with Bonferroni correction 
and Student’s t test. Data represent means and standard 
deviation (means ± SD). A P value of ≤.05 was considered 
statistically significant.
Results and Discussion
Table 1 shows the clinical and biochemical characteristics 
of CN, T0, and T1 infants. Treatment of the patient groups 
ranged from 3–15 days (median, 6 days) and consisted of 
at least 75% of the required energy delivered via PN. Lipids 
were provided through a soybean oil–based emulsion 
(Intralipid 20%; FreseniusKabi, Italy). The average amounts 
of lipid, glucose, and nitrogen administered were1.38 ± 
0.74, 6.8 ± 1.79, and 1.7 ± 0.44 g/kg/d, respectively.19 There 
were no differences in clinical characteristics among the 3 
groups, with the exception of birth weight of the T0 group 
and total bilirubin of the T0 and T1 groups as compared 
with CN infants. Table 2 shows the plasma concentrations 
of glycine- and taurine-conjugated BA for each group. 
Plasma concentrations of glycine- and taurine-conjugated 
BA in term and preterm newborns before PN and at least 
12 hours after the end of the last infusion were measured 
to determine whether there were differences between 
these 2 groups of patients and healthy newborns.
BA concentrations in the CN and T0 groups were not 
statistically significant with the exception of GCA, which 
was significantly elevated (approximately 3.5-fold) in the T0 
group, perhaps due to individual variability in that particular 
group, since it included premature newborns (7 of 9 sub-
jects were premature). Moreover, the comparison of BA 
concentrations in the T0 and T1 groups was not statistically 
significant even though some BA in the T0 group, on 
average, were lower than in the T1 group (Table 2; 
GCDCA+GDCA+GUDCA, TCDCA+TDCA+ TUDCA, and 
TCA). By comparison, after PN, patients had significantly 
increased levels of GCA, TCDCA+ TDCA+TUDCA, and 
TCA as compared with CN infants. There were no signifi-
cant differences among the groups in the concentrations of 
glycolithocholic acid (GLCA), GCDCA+GDCA+GUDCA, 
and taurine-conjugated lithocholic acid (TLCA). Additionally, 
in the T1 group, the concentrations of alanine transami-
nase, γ-glutamyltransferase, and total bilirubin in plasma did 
not correlate with levels of BA; however, the concentration 
of TCA correlated positively with duration of PN (r = 0.547; 
P < .01). These results indicate that plasma BA profiles 
could potentially serve as indicators of metabolic disorders 
and liver disease, as well sensitive indicators of cholestasis.
Table 2.  Plasma Levels (µM) of Conjugated Bile Acids in Healthy Control (CN) Infants and in 
Patients Before (T0) and After (T1) Parenteral Nutrition (PN), Reported as Mean (SD)
Conjugated Bile Acids CN (n = 15) Before PN, T0 (n = 9)           After PN, T1 (n = 22)
GLCA 0.15 (0.06) 0.15 (0.11) 0.14 (0.11)
GCDCA+GDCA+GUDCA 1.83 (1.30) 1.34 (0.75) 5.18 (7.35)
GCA 2.30 (2.60) 7.29 (5.39)a 7.61 (6.46)a
TLCA 0.11 (0.07) 0.23 (0.20) 0.21 (0.20)
TCDCA+TDCA+TUDCA 4.81 (3.49) 6.46 (5.14) 13.58 (12.22)a
TCA 4.02 (3.49) 5.81 (4.13) 11.88 (11.05)a
GCA, glycocholic acid; GCDCA + GDCA + GUDCA, glycochenodeoxycholic + glycodeoxycholic + glycoursodeoxycholic acids; GLCA, 
glycolithocholic acid; TCA, taurocholic acid; TCDCA+TDCA + TUDCA, taurochenodeoxycholic + taurodeoxycholic + tauroursodeoxy-
cholic acids; TLCA, taurine-conjugated lithocholic acid. 
aP < .05 vs CN (analysis of variance with Bonferroni correction).
 at ALBERT EINSTEIN COLG OF MED on September 26, 2010pen.sagepub.comDownloaded from 
Plasma Levels of Conjugated Bile Acids in Newborns / D’Apolito et al  541
PN is associated with changes in plasma BA composi-
tion; the excess amounts of some BA cause hepatotoxic 
effects related to PN, and the administration of taurine 
can decrease the toxicity of BA. Conjugation of BA to 
taurine and glycine is mediated by the same competitive 
enzyme,20 and in preterm infants, where the taurine is a 
provisionally essential amino acid, due to either an inabil-
ity of endogenous synthesis or a nutrition deficit, conju-
gation of BA with glycine would be expected to increase. 
In fact, in the current study, GCA concentrations were 
significantly elevated in the T0 group (Table 2) as com-
pared with healthy controls, which we attribute to the 
number of preterm infants in the T0 group (7/9). It is well 
documented that patients with liver disease have high 
levels of taurine conjugation, while high levels of glycine 
conjugation are typical in patients with malabsorption 
and intestinal bile loss.21 Our data demonstrate that there 
is an early increase in glycine- and taurine-conjugated BA 
in the plasma of newborns receiving PN for 3–15 days. 
Even if only 2 of the patients who received PN developed 
cholestasis during or after the administration of parenteral 
solution, our results indicate that changes in the levels of 
plasma BA could serve as an early marker of liver injury. 
These results are consistent with literature reports that 
increased levels of conjugated BA are indicative of hepatic 
diseases and are in line with the proposal by Demircan 
et al22 that serum BA may be more useful for the early 
diagnosis of PN-induced cholestasis than liver markers 
such as γ-glutamyltransferase and alkaline phosphatase. 
In addition, even though we did not measure the sulfated 
BA, our results are in agreement with those reported by 
Farrell et al,23 in which serum sulfated lithocholate levels 
were elevated in 18 of 55 patients during PN in infants 
and children. Importantly, even if the number of patients 
in each group is small, the data obtained from this pilot 
study suggest for the first time that in newborns, a short 
period of PN is associated with an early and significant 
increase in glycine- and taurine-conjugated BA. Finally, 
the results may encourage researchers to perform larger 
randomized trials, which could lead to identifying the role 
of BA as marker for cholestasis and PN-associated liver 
disease.
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